
MBX Biosciences, Inc.: updates and filings
Price
$53.42
November 18, 2026Market cap $2.5B
What Ploutos Investor adds for MBX Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
October 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Shares registered for employeesFormS-8
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 22, 2026Officer or director changeForm8-K
- Aug 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 10, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 10, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 13, 2026Officer or director changeForm8-K
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 24, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 12, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 5, 2026Officer or director change, shareholder voteForm8-K
- May 11, 2026Regulation FD disclosure, other material eventsForm8-K
- May 8, 2026Additional annual meeting materialFormDEFA14A
- May 7, 2026Results of operationsForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | S-8 | Shares registered for employees | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 22, 2026 | 8-K | Officer or director change | Document |
| Aug 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 10, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 10, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 13, 2026 | 8-K | Officer or director change | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 24, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 12, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 5, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 11, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 8, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 10, 2019.
The full analysis
What do MBX Biosciences's filings show?
The filings are where every one of MBX Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.